Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Masato Takahashi; Javier Cortes; Rebecca Dent; Lajos Pusztai; Heather Mcarthur; Sherko Kuemmel; Carsten Denkert; Yeon Hee Park; Seock-Ah Im; Jin-Hee Ahn; Hirofumi Mukai; Chiun-Sheng Huang; Shin-Cheh Chen; Min Hwan Kim; Liyi Jia; Xin Tong Li; Konstantinos Tryfonidis; Vassiliki Karantza; Hiroji Iwata; Peter Schmid

doi:10.1016/j.annonc.2022.05.066

Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Masato Takahashi, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather Mcarthur, Sherko Kuemmel, Carsten Denkert, Yeon Hee Park, Seock-Ah Im, Jin-Hee Ahn, Hirofumi Mukai, Chiun-Sheng Huang, Shin-Cheh Chen, Min Hwan Kim, Liyi Jia, Xin Tong Li, Konstantinos Tryfonidis, Vassiliki Karantza, Hiroji Iwata, Peter Schmid

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.05.066
State	Published - 2022

Access to Document

10.1016/j.annonc.2022.05.066

Cite this

Takahashi, M., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kuemmel, S., Denkert, C., Park, Y. H., Im, S.-A., Ahn, J.-H., Mukai, H., Huang, C.-S., Chen, S.-C., Kim, M. H., Jia, L., Li, X. T., Tryfonidis, K., Karantza, V., Iwata, H., & Schmid, P. (2022). Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup. Annals of Oncology, 33. https://doi.org/10.1016/j.annonc.2022.05.066

@article{363c776d4705449dbcf72dec5625d8f3,

title = "Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup",

author = "Masato Takahashi and Javier Cortes and Rebecca Dent and Lajos Pusztai and Heather Mcarthur and Sherko Kuemmel and Carsten Denkert and Park, \{Yeon Hee\} and Seock-Ah Im and Jin-Hee Ahn and Hirofumi Mukai and Chiun-Sheng Huang and Shin-Cheh Chen and Kim, \{Min Hwan\} and Liyi Jia and Li, \{Xin Tong\} and Konstantinos Tryfonidis and Vassiliki Karantza and Hiroji Iwata and Peter Schmid",

year = "2022",

doi = "10.1016/j.annonc.2022.05.066",

language = "American English",

volume = "33",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Takahashi, M, Cortes, J, Dent, R, Pusztai, L, Mcarthur, H, Kuemmel, S, Denkert, C, Park, YH, Im, S-A, Ahn, J-H, Mukai, H, Huang, C-S, Chen, S-C, Kim, MH, Jia, L, Li, XT, Tryfonidis, K, Karantza, V, Iwata, H & Schmid, P 2022, 'Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup', Annals of Oncology, vol. 33. https://doi.org/10.1016/j.annonc.2022.05.066

TY - JOUR

T1 - Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

AU - Takahashi, Masato

AU - Cortes, Javier

AU - Dent, Rebecca

AU - Pusztai, Lajos

AU - Mcarthur, Heather

AU - Kuemmel, Sherko

AU - Denkert, Carsten

AU - Park, Yeon Hee

AU - Im, Seock-Ah

AU - Ahn, Jin-Hee

AU - Mukai, Hirofumi

AU - Huang, Chiun-Sheng

AU - Chen, Shin-Cheh

AU - Kim, Min Hwan

AU - Jia, Liyi

AU - Li, Xin Tong

AU - Tryfonidis, Konstantinos

AU - Karantza, Vassiliki

AU - Iwata, Hiroji

AU - Schmid, Peter

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.05.066

DO - 10.1016/j.annonc.2022.05.066

M3 - Journal Article

SN - 0923-7534

VL - 33

JO - Annals of Oncology

JF - Annals of Oncology

ER -